Technical Analysis for MDNA - Medicenna Therapeutics Corp.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | 0.62% | |
| NR7 | Range Contraction | 0.62% | |
| Lower Bollinger Band Walk | Weakness | 0.62% |
| Alert | Time |
|---|---|
| Possible NR7 | about 8 hours ago |
| Up 2% | about 10 hours ago |
| Rose Above Previous Day's High | about 12 hours ago |
| Up 1% | about 12 hours ago |
| Possible Inside Day | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 2024-11-12
Medicenna Therapeutics Corp. Description
Medicenna Therapeutics Corp, formerly A2 Acquisition Corp, is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The Company focuses on commercialization EC and Superkines for the treatment of cancer. The Company's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The Company's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinic Drug Cancer Medical Specialties Oncology Clinical Trial Clinical Medicine Cancers Tumor Immunotherapy Treatment Of Cancer Cancer Immunotherapy Stem Cells Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.98 |
| 52 Week Low | 0.38 |
| Average Volume | 82,919 |
| 200-Day Moving Average | 1.944 |
| 50-Day Moving Average | 2.104 |
| 20-Day Moving Average | 2.110 |
| 10-Day Moving Average | 1.900 |
| Average True Range | 0.200 |
| RSI (14) | 35.06 |
| ADX | 24.96 |
| +DI | 14.852 |
| -DI | 35.097 |
| Chandelier Exit (Long, 3 ATRs) | 2.019 |
| Chandelier Exit (Short, 3 ATRs) | 1.871 |
| Upper Bollinger Bands | 2.769 |
| Lower Bollinger Band | 1.450 |
| Percent B (%b) | 0.13 |
| BandWidth | 62.527 |
| MACD Line | -0.159 |
| MACD Signal Line | -0.070 |
| MACD Histogram | -0.0885 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.695 | ||||
| Resistance 3 (R3) | 1.697 | 1.673 | 1.683 | ||
| Resistance 2 (R2) | 1.673 | 1.654 | 1.673 | 1.678 | |
| Resistance 1 (R1) | 1.647 | 1.642 | 1.660 | 1.645 | 1.674 |
| Pivot Point | 1.623 | 1.623 | 1.630 | 1.623 | 1.623 |
| Support 1 (S1) | 1.597 | 1.604 | 1.610 | 1.595 | 1.566 |
| Support 2 (S2) | 1.573 | 1.592 | 1.573 | 1.562 | |
| Support 3 (S3) | 1.547 | 1.573 | 1.558 | ||
| Support 4 (S4) | 1.545 |
